VP4-2023: Sotorasib 960 mg versus 240 mg in pretreated KRAS G12C advanced NSCLC

被引：10

作者：

Hochmair, M. J. ^{[1
]}

Vermaelen, K. ^{[2
]}

Mountzios, G. ^{[3
,4
]}

Carcereny, E. ^{[5
]}

Dooms, C. ^{[6
]}

Lee, S. -h. ^{[7
]}

Morocz, E. M. ^{[8
]}

Kato, T. ^{[9
]}

Ciuleanu, T-e. ^{[10
]}

Dy, G. ^{[11
]}

Parente, M. B. M. C. S. ^{[12
]}

O'Byrne, K. J. ^{[13
]}

Chu, Q. s -c. ^{[14
]}

De Castro Jr, G. ^{[14
]}

Girard, N. ^{[15
]}

Snyder, W. ^{[16
]}

Tran, Q. ^{[16
]}

Kormany, W. ^{[16
]}

Houk, B. ^{[16
]}

Curioni-Fontecedro, A. ^{[17
]}

机构：

[1] Karl Landsteiner Inst Lung Res & Pulm Oncol, Dept Resp & Crit Care Med, Klin Florisdorf, Vienna, Austria

[2] UZ Gent Univ Ziekenhuis Gent, Dept Pulm Med, Ghent, Belgium

[3] Henry Dunant Hosp Ctr, Dept Med Oncol 4, Athens 11526, Greece

[4] Henry Dunant Hosp Ctr, Clin Trials Unit, Athens, Greece

[5] Catalan Inst Oncol Badalona, Badalona Appl Res Grp Oncol, Med Oncol, Badalona, Spain

[6] Univ Hosp KU Leuven, Dept Resp Dis, Leuven, Belgium

[7] Sungkyunkwan Univ, Samsung Med Ctr SMC, Dept Med, Div Hematol Oncol,Sch Med, Seoul, South Korea

[8] Pest Cty Hosp Pulmonol, Pulmonolgy, Torokbalint, Hungary

[9] Kanagawa Canc Ctr, Thorac Oncol Dept, Yokohama, Japan

[10] IOCN Oncol Inst Prof Dr Ion Chiricuta, Med Oncol Dept, Cluj Napoca, Romania

[11] Roswell Park Comprehens Canc Ctr, Med Dept, Buffalo, NY USA

[12] CHVNG E Ctr Hosp Vila Nova Gaia Espinho, Unidade 1, Pulmonol, EPE SNS, Porto, Portugal

[13] Princess Alexandra Hosp, Canc Serv, Metro South Hlth, Woolloongabba, Qld, Australia

[14] Univ Alberta, Cross Canc Inst, Med Oncol, Edmonton, AB, Canada

[15] Thorax Inst, Inst Curie, Paris, France

[16] Amgen Inc, Oncol, Thousand Oaks, CA USA

[17] Univ Hosp Zurich, Dept Med Oncol & Hematol, Zurich, Switzerland

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷 / 01期

关键词：

D O I：

10.1016/j.annonc.2023.10.790

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：142 / 144

页数：3

共 50 条

[11] Durability of Clinical Benefit and Biomarkers in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Sotorasib, a KRAS(G12C) Inhibitor
Hong, D. S.
Bang, Y. -J.
Barlesi, F.
Durm, G.
Falchook, G.
Govindan, R.
Dy, G.
Park, K.
Strickler, J.
Burns, T.
Kim, J.
Ang, A.
Lipford, J. R.
Ngarmchamnanrith, G.
Anderson, A.
Li, B. T.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S28 - S29
[12] Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C (vol 389, pg 2125, 2023)
Fakih, Marwan G.
NEW ENGLAND JOURNAL OF MEDICINE, 2025, 392 (07): : 728 - 728
[13] CodeBreaK 200: A Phase 3 Multicenter Study of Sotorasib, a KRAS(G12C) Inhibitor, versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS p.G12C Mutation
Reck, M.
Spira, A.
Besse, B.
Wolf, J.
Skoulidis, F.
Borghaei, H.
Goto, K.
Park, K.
Griesinger, F.
Font, E. F.
Boyer, M.
Barrios, C. H.
Goss, G.
Yang, H.
Obiozor, C.
Ramalingam, S.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S29 - S29
[14] Synergistic antitumor activity of nab-sirolimus in combination with KRAS inhibitors (KRASis) sotorasib and adagrasib in KRAS G12C NSCLC and bladder cancer xenografts
Hou, Shihe
Kwon, Andrew
Nieva, Jorge
Desai, Neil
CANCER RESEARCH, 2023, 83 (07)
[15] CodeBreaK 101: Safety and Efficacy of Sotorasib with Carboplatin and Pemetrexed in KRAS G12C-Mutated Advanced NSCLC
Clarke, J. M.
Felip, E.
Li, B. T.
Ruffinelli, J. C.
Garrido, P.
Zugazagoitia, J.
Goldberg, S. B.
Ramalingam, S. S.
Victoria, I.
Puri, S.
Gandara, D. R.
Varrieur, T.
Edmonds, S.
Palmer, K.
Snyder, W.
Govindan, R.
Rybkin, I.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S118 - S119
[16] Overcoming amplification-mediated resistance to sotorasib by dose re-escalation in KRAS G12C mutant NSCLC: a case report
Vitale, Antonio
Vita, Emanuele
Stefani, Alessio
Cancellieri, Alessandra
Lococo, Filippo
Tortora, Giampaolo
Bria, Emilio
ONCOLOGIST, 2025, 30 (03):
[17] Sotorasib long-term clinical outcomes in pretreated KRAS G12C-mutated advanced NSCLC: Pooled analysis from the CodeBreaK clinical trials
Skoulidis, F.
Li, B. T.
Hochmair, M. J.
Govindan, R.
Vincent, M.
Van der Wekken, A. J.
Reguart Aransay, N.
O'Byrne, K. J.
Girard, N.
Griesinger, F.
Nishio, M.
Hafliger, S.
Lindsay, C.
Reinmuth, N.
Paulus, A.
Papakotoulas, P.
Obiozor, C.
Nduka, C.
Wang, Y.
De Langen, A. J.
ANNALS OF ONCOLOGY, 2024, 35 : S830 - S831
[18] CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation
Reck, M.
Spira, A.
Besse, B.
Wolf, J.
Skoulidis, F.
Borghaei, H.
Goto, K.
Park, K.
Griesinger, F.
Felip, E.
Boyer, M.
Barrios, C. H.
Goss, G.
Yang, H.
Obiozor, C.
Ramalingam, S. S.
ANNALS OF ONCOLOGY, 2020, 31 : S894 - S895
[19] Clinical utility of circulating tumor DNA in patients with advanced KRAS G12C-mutated NSCLC treated with sotorasib
Ernst, Sophie M.
van Marion, Ronald
Atmodimedjo, Peggy N.
de Jonge, Evert
Mathijssen, Ron H.
Paats, Marthe S.
de Bruijn, Peter
van Schaik, Ron H. N.
Dubbink, Hendrikus J.
Dingemans, Anne-Marie C.
CANCER RESEARCH, 2023, 83 (07)
[20] Registrational phase 2 trial of sotorasib in KRAS p. G12C mutant NSCLC: first disclosure of the CodeBreaK 100 primary analysis
Schuler, M.
Li, B. T.
Skoulidis, F.
Falchook, G.
Sacher, A.
Velcheti, V.
Dy, G. K.
Price, T.
Borghaei, H.
Kato, T.
Takahashi, T.
Spira, A.
Ramalingam, S.
Besse, B.
Barlesi, F.
Tran, Q.
Henary, H.
Ngarmchamnanrith, G.
Govindan, R.
Wolf, J.
PNEUMOLOGIE, 2021, 75 : S38 - S38

← 1 2 3 4 5 →